Search This Blog

Wednesday, September 30, 2020

AstraZeneca/Oxford COVID-19 vaccine nabs accelerated review in Europe

Bloomberg reports that the European Medicines Agency (EMA) has agreed to a rolling review of the marketing application for AstraZeneca (AZN -0.3%) and the University of Oxford's COVID-19 vaccine (AZD1222/ChAdOx1).

The timing of the filing should be next year since topline data from two pivotal large-scale studies will not likely be available until then.

https://seekingalpha.com/news/3618516-astrazeneca-oxford-covidminus-19-vaccine-nabs-accelerated-review-in-europe

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.